People with moderate or severe hemophilia had worse joint status, lower pain thresholds, and poorer quality of life compared with people with mild hemophilia or healthy controls.
Therapeutic advances in the treatment of hemophilia, particularly the introduction of prophylaxis using recombinant factors, have greatly reduced bleeding and improved the lives of patients. This advancement has also increased life expectancy, making it comparable to the general population. Accordingly, healthcare providers are seeing more older adults with hemophilia, including those who are living with comorbidities such as joint pain and functional limitations.
In people with severe hemophilia A, previous research has shown that not receiving prophylaxis early in life leads to joint damage that cannot be reversed, even with later prophylaxis. Limited research has been done to assess the joint and health status of elderly individuals with mild hemophilia.
To gain a better understanding of these issues, a group of researchers, led by Valérie-Anne Chantrain, Ph.D. candidate at the University of Antwerp in Brussels, Belgium, conducted a case-control study exploring functional status and quality of life in older adults with hemophilia. The paper was published October 2023 in Haemophilia.
More specifically, the objective of this study was to compare the joint status, pain, and health-related quality of life (HR-QoL) between elderly individuals with mild hemophilia, moderate/severe hemophilia, and those without hemophilia (healthy controls).
To accomplish this, the researchers recruited 60 participants ages 60 years or older, including 40 adults with hemophilia A/B (23 mild; 17 moderate/severe) and 20 age-matched healthy controls. All participantsunderwent both ultrasound imaging and physical exams to identify and evaluate any abnormalities in the knees and ankles. Pain thresholds were measured at the knees, ankles, and forehead. Physical activity and movements were assessed via several functional tests, including a two-minute walking test. All participants also completed questionnaires to assess pain severity and health-related quality of life (HR-QoL).
The results showed that people with moderate/severe hemophilia had worse joint status, lower pain thresholds, and poorer quality of life compared with people with mild hemophilia and healthy controls. Joint abnormalities, pain, functional decline, and poor quality of life were also observed in some patients with mild hemophilia, but they did not significantly differ from the healthy controls. Ultrasound abnormalities were observed in the knees and ankles of nearly all participants with moderate/severe hemophilia. In comparison, ultrasound abnormalities were seen in 50% of knees and 61% of ankles in participants with mild disease.
The findings highlight the importance of addressing these health issues in older adults with hemophilia, including those with mild hemophilia. The authors wrote, “Based on the correlation analysis, pain and joint pain sensitivity were only lowly-to-moderately associated with joint status, as observed in adults with moderate/severe hemophilia. Considering the latter, findings encourage future research to address pain beyond a purely biomedical lens in hemophilia.”
Hemgenix Gene Therapy Shows Long-Term Efficacy, Safety in Hemophilia B Patients
December 21st 2023Men with severe or moderately severe hemophilia B continue to display low bleeding rates and very little use of replacement therapies for at least three years following a single dose of the approved gene therapy hemgenix.
Read More
Bridging the Diversity Gap in Rare Disease Clinical Trials with Harsha Rajasimha of IndoUSrare
November 8th 2023Briana Contreras, an editor with Managed Healthcare Executive, spoke with Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, in this month's episode of Tuning in to the C-Suite podcast. The conversation was about how the disparity in diversity and ethnicity in rare disease clinical trials in the U.S. has led to gaps in understanding diseases and conditions, jeopardizing universal health, and increasing the economic burden of healthcare.
Listen
FDA Approves Adzynma for Rare Blood Clotting Disorder cTTP
November 27th 2023CTTP is rare hereditary blood clotting disorder stemming from a disease-causing mutation in the ADAMTS13 gene. This gene plays a crucial role in producing the ADAMTS13 enzyme, responsible for regulating blood clotting.
Read More
Diversity Gaps in U.S. Rare Disease Trials and the Inequalities in Hemophilia Clinical Studies
November 17th 2023Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, spoke to MHE about the current disparities in diversity and ethnicity in rare disease clinical trials in the U.S., as well as what he's seeing in clinical trials for diseases like hemophilia, in specific.
Read More